Skip to content
Our 🎯 Q1 2026 Psychedelic Pipeline Bullseye Charts are now available.
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
Menu
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
Menu
  • Pα+
Search
Join Pα+
  • Sign in
Menu
  • Sign in
Join Pα+
Search
Close this search box.
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Menu
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Join Pα+
Search
Close this search box.
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Menu
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Read more about the article Field Trip Health Ltd. Announces Completion of DMPK Studies, Engineering Batch for FT-104, Its Novel Psychedelic Compound

Field Trip Health Ltd. Announces Completion of DMPK Studies, Engineering Batch for FT-104, Its Novel Psychedelic Compound

  • Post published:June 15, 2021
  • Post category:Press Release
Read more about the article Psychedelic Research Bulletin: May 2021

Psychedelic Research Bulletin: May 2021

  • Post published:June 14, 2021
  • Post category:Psychedelics Research Review
Read more about the article Psychedelic Bulletin: MindMed CEO Steps Down; Atai Targets $2.3bn Valuation

Psychedelic Bulletin: MindMed CEO Steps Down; Atai Targets $2.3bn Valuation

  • Post published:June 11, 2021
  • Post category:Psychedelic Bulletin
Read more about the article Filament Announces First GMP Batch of Pharmaceutical Grade Natural Psilocybin

Filament Announces First GMP Batch of Pharmaceutical Grade Natural Psilocybin

  • Post published:June 11, 2021
  • Post category:Press Release
Read more about the article atai Life Sciences Announces Launch of Initial Public Offering

atai Life Sciences Announces Launch of Initial Public Offering

  • Post published:June 11, 2021
  • Post category:Press Release
Read more about the article Atai Targets $2.3bn Valuation in Nasdaq IPO

Atai Targets $2.3bn Valuation in Nasdaq IPO

  • Post published:June 11, 2021
  • Post category:News
Read more about the article Entheon Biomedical’s Wholly-Owned Subsidiary, HaluGen Life Sciences, Psychedelics Genetic Test Kit Now Available for Sale in US

Entheon Biomedical’s Wholly-Owned Subsidiary, HaluGen Life Sciences, Psychedelics Genetic Test Kit Now Available for Sale in US

  • Post published:June 10, 2021
  • Post category:Press Release
Read more about the article Red Light Holland Closes Acquisition of 80% of Happy Caps Mushroom Farm – Specializing in Grow-At-Home Mushroom Kits

Red Light Holland Closes Acquisition of 80% of Happy Caps Mushroom Farm – Specializing in Grow-At-Home Mushroom Kits

  • Post published:June 10, 2021
  • Post category:Press Release
Read more about the article PharmaTher Provides Research and Development Update and Milestones for 2021

PharmaTher Provides Research and Development Update and Milestones for 2021

  • Post published:June 10, 2021
  • Post category:Press Release
Read more about the article MYND Life Sciences Announces Patent Applications for Depression and Neuropsychiatric Disorder Drugs

MYND Life Sciences Announces Patent Applications for Depression and Neuropsychiatric Disorder Drugs

  • Post published:June 10, 2021
  • Post category:Press Release

End of content

No more pages to load

← Newer Posts
Older Posts →

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond. Psy Alpha Ltd is a company registered in England and Wales (16989109).

Quick Links

  • Insights
  • Jobs
  • Data
  • Subscribe to Pα+
  • Contact

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.

Subscribe to Pα+
  • Psychedelic Alpha © 2026, All Rights Reserved
  • Privacy Policy
  • Terms of Service

Subscribe to Our Free Newsletter

Join Pα+ for Premium Insights

Subscribe Annually ($200)
Subscribe Monthly ($20)
Learn More